Donald C. Manning, MD, PhD
Chief Medical Officer
Previously
- Founder and President of Arpeggio Pharma Consultants LLC
- CMO of Travecta Therapeutics, Pacira Biosciences, Adynxx Inc and Shionogi Inc
- VP of Neuroscience, Celgene
- Associate Professor of Anesthesiology, Critical Care and Pain Medicine University of Virginia
Donald C. Manning, MD, PhD
Chief Medical Officer
Previously
- Founder and President of Arpeggio Pharma Consultants LLC
- CMO of Travecta Therapeutics, Pacira Biosciences, Adynxx Inc and Shionogi Inc
- VP of Neuroscience, Celgene
- Associate Professor of Anesthesiology, Critical Care and Pain Medicine University of Virginia
Don is a clinician-scientist and top corporate officer with comprehensive experience in acute and chronic clinical practice, research, and management within academic and industrial settings. He is proficient in all aspects of drug development from target selection through development, approval, and medical affairs in a wide range of therapeutic areas. Most recently he was president and founder of Arpeggio Pharma Consultants, advising pharma and biotech organizations. Over the past 25 years, with 15 as Chief Medical Officer, he has held positions of increasing responsibility in established and startup companies including Novartis, Celgene, Shionogi and Adynxx Inc. He has filed 7 INDs and 5 NDAs that have led to 9 approved products. He has held clinical academic faculty positions in the Departments of Anesthesiology at Johns Hopkins University and The University of Virginia Health Sciences Center. At Johns Hopkins University and Hospital, he received his Ph.D. in Pharmacology, an M.D., research fellowship training in Anesthesiology and Neurosurgery, and a residency in Anesthesiology and Critical Care Medicine with a subspecialty in Pain Management. He received a B.Sc. in physiology and biochemistry from McGill University.